Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments.

Front Neurol · 2017 · PMC5686062 · PMID 29176956

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The results of ASCEND trial (Table 1 ; Figure 3 ), in which more SPMS patients treated with natalizumab achieved sustained disability progression in comparison with placebo (although the difference did not reach statistical significance), should not be ignored.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.